Название документа

German medicine Vetmedin is created for treatment of pathologies of heart at dogs. Medicine is appointed by the veterinarian at heart failure at the pet. High responses of doctors and experienced manufacturers, demonstrate efficiency of means. The fact that it increases vital activity of the pet belongs to additional benefits of medicine. Thanks to a convenient form of release - chewable tablets, the dog with pleasure will eat the offered medicine.

Vetmedin is used in veterinary practice. Tablets are appointed to dogs with heart failure. Medicine is effective if the etiology is in dysfunction of heart valves or stretching of a cardiac cavity.

Systematic application of tablets allows to improve a condition of an animal, to eliminate such symptoms as faints, the complicated breath. Also regular use of a pimobendan improves physical activity of a dog.

Active ingredient of means – pimobendan. One tablet contains 5 mg of a basic component. Also is vetmedin 1.25 mg; 2.5 mg, 10 mg.

Instruction:

Vetmedin® of Chu (Vetmedin® Chew), chewable tablets No. 100

Brown, oval chewable tablet, shares and has the line of a break on both sides.

Structure:

One tablet (0.2 g) contains active ingredient:

pimobendan - 1.25 mg.

One tablet (0.8 g) contains active ingredient:

pimobendan - 5 mg.

One tablet (1.6 g) contains active ingredient:

pimobendan - 10 mg.

Excipients: lactose monohydrate, microcrystalline cellulose, starch corn, sodium of starch glikolit (type A), a macrogoal 6000, stearoilmakrogolglitserida, dried yeast, hepatic powder fragrance, talc, magnesium stearate.

Pharmacological properties:

ATC vet classification QC01CE90 code - Neglikozidny cardiotonic veterinary medicines. Phosphodiesterase inhibitors. Pimobendan.

Pimobendan, derivative a benzimadazol-piridazinona, has positively inotropny action and has the expressed vasodilating (vazodilatatorny) properties.

Positive inotropny effect of a pimobendan is caused by two mechanisms of action: increase in sensitivity to calcium of fibers of a cardiac muscle and oppression of activity of phosphodiesterase III. Thus, the positive inotropny effect is not caused the action similar to effect of cardiac glycosides, simpatomimetichesky. The Vazodilatiruyushchy effect is connected with oppression of activity of phosphodiesterase III.

In cases of symptomatic insufficiency of valves of heart, at application in combination with furosemide, it was shown that medicine improves quality and increases the expected life expectancy of dogs which were treated.

It was shown that in limited quantity of cases, at application in cases of a symptomatic dilatatsionny cardiomyopathy in combination with furosemide, enalapril and digoxin, medicine improves quality and increases the expected life expectancy at dogs.

After oral application of a pimobendan the bioavailability is it 60-63%. As simultaneous or preliminary consumption of food reduces bioavailability, pimobendan it is necessary to enter approximately in 1 hour prior to feeding of an animal.

Volume of distribution is 2.6 l/kg that indicates what pimobendan is evenly distributed in fabrics. The average of linking with proteins of plasma makes 93%.

Connection demetilirutsya by

by oxidation to the main metabolite (UD-CG212). The subsequent metabolic stages are conjugates of the II phase UD-CG212, such as glyukuronida and sulfates.

Elimination half-life of a pimobendan makes of plasma of blood 0.4 ± 0.1 hours that corresponds to high clearance 90 ± 19 ml/min. and the short average time of deduction 0.5 ± 0.1 hours. The most considerable active metabolite is brought out of blood plasma with elimination half-life 2.0 ± 0.3 hours. Almost all dose is removed with a stake.

Application:

For treatment of the stagnant heart failure at dogs arising owing to a dilatatsionny cardiomyopathy or valve insufficiency (regurgitation of mitralny and/or tricuspid valves).

For treatment of a dilatatsionny cardiomyopathy at a preclinical stage (an asymptomatic current with increase in final and systolic and final diastolic diameter of the left ventricle) at a Dobermann terrier pinschers after echocardiographic diagnosis of a disease of heart.

For treatment of dogs with miksomatozny mitralny heart disease (MMVS) in a preclinical stage (an asymptomatic current with systolic mitralny noise and signs of increase in the sizes of heart) for a delay of emergence of clinical symptoms of heart failure.

For treatment of dogs with body weight from 5 kg to 10 kg Chus Vetmedin® in a dosage of 1.25 mg use
For treatment of dogs with body weight from 20 kg to 40 kg use Chus Vetmedin® in a dosage of 5 mg
For treatment of dogs with body weight from 40 kg to 60 kg use Chus Vetmedin® in a dosage of 10 mg

Dosage:

needs to determine by

Before an initiation of treatment the exact body weight of an animal to provide the correct dosage.

Should observe a dosage from 0.2 mg to 0.6 mg of a pimobendan on 1 kg of body weight divided into two receptions a day.

Recommended daily dose makes 0.5 mg of a pimobendan on 1 kg of body weight, divided into two receptions.

One chewable tablet (1.25 mg) in the morning and one chewable tablet (1.25 mg) in the evening for body weight from 5 kg to 10 kg.

One chewable tablet (5 mg) in the morning and one chewable tablet (5 mg) in the evening for body weight from 20 kg to 40 kg.

One chewable tablet (10 mg) in the morning and one chewable tablet (10 mg) in the evening for body weight from 40 kg to 60 kg.

Feature of application:

do not exceed the recommended dose.

Medicine is applied orally.

Apply

approximately for an hour before feeding.

Medicine can be applied in combination with diuretic, for example furosemide.

For more exact dispensing that corresponds to the body weight of an animal, a tablet can be divided in the area of a break into two halves.

Contraindication:

not to apply

pimobendan at a hypertrophic cardiomyopathy or at clinical states where it is possible to increase warm emission of blood through functional or anatomic features (for example, an aorta stenosis).

As metabolism of a pimobendan happens mainly through a liver, medicine should not be applied at dogs with heavy dysfunction of a liver.

Side effect:

In rare instances can observe insignificant positive hronotropny effect (increase in heart rate) and vomiting. However these effects of a dozozavisima and them it is possible to avoid due to reduction of a dose of medicine.

are observed In rare instances by symptoms of tranzitorny diarrhea, lack of appetite or slackness.

In rare instances, at long-term treatment pimobendany at dogs with mitralny heart disease, observe increase in a regurgitation of the mitralny valve.

Though connection with action of a pimobendan was not accurately established by

Special cautions when using:

Should check regularly glucose level in blood at treatment of dogs with diabetes.

needs to carry out by

For use of medicine for the purpose of treatment of a dilatatsionny cardiomyopathy at a preclinical stage (an asymptomatic current with increase in final and systolic and final diastolic diameter of the left ventricle) diagnostics by comprehensive warm examination (including an echocardiographic research and, perhaps, holterovsky monitoring).

For use of medicine for the purpose of treatment of miksomatozny mitralny heart disease in a preclinical stage (B2 stage, according to consensus of ACVIM: the asymptomatic current with mitralny noise> 3/6 and a kardiomegaliya, owing to miksomatozny mitralny heart disease) needs to be carried out diagnostics by comprehensive physical and cardiological examination which has to include, if necessary, an echocardiography or a X-ray analysis.

recommends monitoring of warm function and morphology at the animals receiving pimobendan.

Tablet flavored. To avoid accidental ingestion, you store tablets in the place, inaccessible for animals.

Use during pregnancy, lactations, a yaytsenoskost

Laboratory researches on rats and rabbits did not reveal any proofs of teratogenny or fetotoksichesky action. However, these researches showed existence of toxic action on pregnant females and found out embriotoksichesky action at use of medicine in high doses and also what pimobendan is allocated in milk. Safety of medicine for pregnant women and the feeding females of dogs was not estimated. Medicine the doctor of veterinary medicine according to assessment can apply only advantage/risk of medicine.

Interaction with other means and other forms of interaction:

At pharmacological researches did not observe interaction between cardiac glycosides by strophanthin and pimobendany. The increase in sokratitelny ability of heart caused pimobendany is weakened by antagonists of calcium verapamil and diltiazemy and the R-antagonist propranolol.

Special cautions:

Medicine was investigated by

in cases of an asymptomatic dilatatsionny cardiomyopathy (DKMP) at Dobermann terriers with fibrillation of auricles or persistent ventricular tachycardia.

Medicine was investigated by

in cases of asymptomatic miksomatozny mitralny heart disease at dogs from a considerable supraventrikulyarny and/or ventricular takhiaritmiya.

release Form:

Blister from aluminum foil with the soldered seams/PVC / the aluminum foil / polyamide containing 10 tablets.

Cardboard box with 2 blisters on 10 tablets (20 tablets).

Cardboard box with 5 blisters on 10 tablets (50 tablets).

Cardboard box with 10 blisters on 10 tablets (100 tablets).

Storage:

Dry place, dark, inaccessible for children, at a temperature not above 25 °C.

Divided tablets should be returned to

an open cellular pocket and to put back in a cardboard box.

Expiration date:

2 years. An expiration date of the divided (halves) of tablets after opening of primary packing of 3 days.

Producer : Boehringer Ingelheim International GmbH Species of an animalDogsCategory of veterinary medicineMedicines of other groupsArea of application of veterinary medicineDiseases of a cardiovascular systemMedicinesChemotherapeutic medicinesFormTablets

Characteristics
Area of application of veterinary medicine	Diseases of a cardiovascular system
Category of veterinary medicine	Medicines of other groups
Drugs	Chemotherapeutic medicines
Release form	Tablets
Species of an animal	Dogs